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Abstract
Background: Individuals with a spinal cord injury (SCI), despite specialized rehabilitation and good health care,
have a reduced life expectancy. Infectious diseases, such as pneumonias, infected pressure sores and urinary tract
infections (UTI) have been identified as the leading causes of mortality. We hypothesise that a premature onset of
immune frailty occurs in SCI, possibly caused also by recurrent urinary tract infections.
A cross sectional study was performed comparing blood and urine samples between able bodied controls (n = 84)
and persons with spinal cord injury (n = 85). The results were grouped according to age (below and above
60 years). Assessed were the abundancies of immune cells, the concentration of soluble biomarkers, the in vitro
functioning of lymphocytes as well as phenotypic exhaustion of T-cells in blood and urine. Further, the leucocyte
telomere length and the cytomegalovirus (CMV) serological status were compared between the groups.
Results: We observed in people with SCI lower proportions of naïve T-cells, more memory T-cells, reduced T-cell
proliferation and higher CMV prevalence compared to age-matched controls. SCI participants older than 60 years
had a higher prevalence of UTI compared with SCI persons younger than 60 years.
Conclusion: The immune system of people with SCI shows traits of an increased immunological strain and a premature
onset of immune frailty. The role of UTI in the onset of immune frailty remains to be elucidated as we did not see
significantly higher abundancies of circulating UTI-bacteria specific T-cell clones in persons with SCI. We assume that any
impact of UTI on the immune system might be compartmentalized and locally restricted to the urinary tract.
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Background
Persons suffering from a spinal cord injury (SCI) face a
broad variety of challenges, SCI linked health issues and
biological changes. Even with improved early medical
health care, specialized rehabilitation and regular follow
up visits today, the longevity of persons with SCI still re-
mains below that of the general population [1, 2]. The
leading cause of death are infectious diseases such as
pneumonia, infected pressure sores and urinary tract in-
fections (UTI) [3]. The reason for the increased infection
rate is still a matter of debate. It has been discussed that
the reduced physical activity, the elevated prevalence of
depression or the exposure to selected medications in
SCI persons have a negative impact on immunological
health [4, 5]. There is evidence that the decentralisation of
the autologous nervous system causes an acute SCI in-
duced immune deficiency syndrome (SCI-IDS) [6] which
manifests as significantly decreased immune cell concen-
tration shortly after a traumatic event. However, a study in
humans [7] demonstrated that 4–5 months after the trau-
matic event, the white blood cell concentration has mostly
normalized, but nonetheless infection rates among people
with SCI remain high. Monahan et al. [8] could show
that individuals with chronic SCI still had reduced
CD4 T-cell concentrations but increased numbers of
activated (HLA-DR+) CD4 T-cells. Otherwise there is
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limited data available on the function of the immune
system in people with SCI in the chronic phase of
the injury and on the precise interplay between cell
types and soluble biomarkers of immunity.
Immune frailty (also referred to as immunosenescence),
manifests as a decline in immune function, a higher sus-
ceptibility to infectious diseases and a reduced response to
vaccines [9, 10]. The age related changes affect both the
innate- and the adaptive immune system but are most
pronounced in the T-cell compartment [11, 12]. Major
changes are the phenotypic shift from naïve- to memory
T-cells [13] and the decrease in T cell receptor diversity
[14]. In addition to the alternations in the composition
and diversity of the T-cell pool, the function of the cells is
also affected by age. T-lymphocytes from frail persons
have typically a reduced in vitro proliferative and signal-
ling response to mitogens compared to their younger
counterparts [15]. Paradoxically and in contrast to the re-
duced function of the immune system a chronic low grade
inflammation, termed inflamm–ageing is observed in frail
elderly people [16]. Often described are age-dependant el-
evated basal levels of interleukine-6 (IL-6), C-reactive pro-
tein (CRP) and tumour necrosis factor α (TNF-α) [17].
There is growing evidence that a chronic cytomegalo-
virus (CMV) infection is a major driving force behind
immunosenescence [18]. The recurrent stimulation with
the CMV antigen leads to several expansion and reduction
cycles of the CMV-specific memory T-cells, eventually
leading to an accumulation of DNA mutations, shortened
telomeres and an exhausted T-cell phenotype [19].
The incidence of SCI peaks in young adults [2] and
therefore their immune system is exposed to UTI over
the majority of their life. A further complication is that
the affected persons often lack sensory function which
increases the risk of a prolonged and undetected bacter-
ial infection.
With this study we aim to investigate if there is a pre-
mature onset of immunosenescence among persons with
SCI which may be partly responsible for the increased
infection rates in the chronic phase of a SCI (>1 year
after incidence). We further hypothesize, that chronic
and recurrent UTI, as they often occur in SCI persons,
could have a similar - CMV- like - effect on the immune
system. We speculate that due to the increased exposure
to UTI causing bacteria the immune system of SCI per-
sons is changed towards a more exhausted and senes-
cent phenotype.
Methods
Study design and sampling
A cross-sectional study with a total of 169 participants
was performed. Included were men with chronic (since
at least one year) SCI and able bodied men who were
not on an drug regimen influencing the immune system.
Only men were recruited in order to avoid bias through
gender specific differences and the inevitable differences
in group sizes due to the greater proportion of males
among SCI patients. Study participants were divided into
four groups: persons with SCI younger than 60 years
(ySCI, n = 42), persons with SCI aged 60 or older (oSCI,
n = 43), and as a control, able bodied persons younger
than 60 years (yCtr, n = 42) and aged 60 or older (oCtr,
n = 42). After written informed consent had been ob-
tained, venous blood and urine samples were collected
during a routine medical check-up.
Blood processing and differential blood count
Venous blood (27 ml) was collected in 2 × 9 ml K3E S-
Monovettes containing EDTA for white blood cell and
plasma isolation, 1 × 4 ml K3E S-Monovette containing
EDTA for differential blood count and 1 × 4.5 ml S-
Monovette for serum isolation (all from Sarstedt). The
obtained blood was stored at room temperature and the
serum at 4 °C for maximum 5 h after phlebotomy.
Peripheral blood mononuclear cells (PBMC) were iso-
lated by H-Lympholyte Cell Separation Media (Cedarlane,
Bioconcept) in a Leucosep tube (Greiner, Sigma-Aldrich)
by gradient centrifugation at 800 g and room temperature
(21 °C air conditioned room) for 20 min. The plasma frac-
tion was collected without disturbing the beneath lying
buffy coat and stored in aliquots at −80 °C. In a next step
the PBMC containing buffy coat was carefully retrieved
and washed with isotonic phosphate buffered saline (PBS),
followed by a centrifugation at 210 g and room
temperature for 10 min. The obtained pellet was resus-
pended in freezing media - 10% dimethyl sulfoxide, 35%
RPMI-1640 medium (Amimed; Bio Concept) and 55%
fetal bovine serum (FBS, Amimed; Bio Concept) - adjusted
to a concentration of 5*106 cells/ml and immediately
transferred to −80 °C in a CoolCell (Biocision) container
ensuring a cooling rate of −1 °C/min. The next day, the
frozen cell suspension was transferred to a long term cryo-
genic storage (−150 °C Ultra-low Temperature freezer
MDF-C2156VAN, Panasonic).
Simultaneously, a differential white blood cell count
and a total serum protein, albumin, C reactive protein
(CRP) and creatinine quantification were performed at a
certified diagnostic laboratory (at the Swiss Paraplegic
Centre in Nottwil, Switzerland).
Urine processing and analysis
Approximately 30 ml of midstream urine were collected
from the controls and the study participants with SCI ei-
ther using a sterile urine cup and a urine monovette
(Sarstedt) or directly from a catheter (intermittent, in-
dwelling or suprapubic). Urine was kept at 4 °C for a
maximum of 5 h before being processed. A urine sample
was analyzed in a certified clinical laboratory (at the
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Swiss Paraplegic Centre in Nottwil, Switzerland) for
creatinine concentration and tested with a urine-Stix test
(Combur 10 Test, Roche) with automated result acquisi-
tion (cobas u 4111). In case of a positive urine-Stix sig-
nal, a leucocyte and microbial quantification of the urine
sediment was performed. If more than 90 leucocytes/ μl
or an elevated microorganism count (> 1*105 /ml was
detected, a subsequent bacteriological analysis was con-
ducted to identify and characterize the infection causing
bacteria. The remaining urine was centrifuged at 4 °C
and 1′800 g for 10 min. The supernatant was aliquoted
and stored at −80 °C until further usage. The urine sedi-
ment pellet was resuspended in 1 ml of residual urine
and also frozen at −80 °C.
Immunoglobulins ELISA assays
Plasma IgG concentration:
An indirect ELISA was done to measure the concentration
of total IgG antibody in plasma as follows: a 96-well plate
(Nunc MaxiSorp, Sigma-Aldrich) was coated with 100 μl of
1 ng/μL Protein A (LuBioScience) in PBS and incubated
overnight at 4 °C, then washed three times with
100 μl of PBS with a plate washer (Beckman-Coulter,
Nyon, Switzerland). Non-specific binding sites were
blocked for 2 h at room temperature with blocking solu-
tion containing 5% TopBlock (LuBioScience) in PBS. After
washing the wells with PBS, thawed plasma aliquots -
cleared of cell debris by centrifugation and diluted 20′000
fold in PBS - were incubated for 2 h at room temperature.
Supernatants were then removed and the wells washed
with PBS. Anti-human-IgG HRP-conjugated secondary
antibody (A80-119P, Bethyl) diluted 1:5′000 in blocking
buffer was incubated for 1 h at room temperature followed
by another washing step with PBS. IgG was determined by
colorimetric measurement of the product of the enzymatic
reaction mediated by HRP and 100 μl/well of o-
phenylenediamine (OPD) solution (15.3 mg/mL in citrate
buffer, pH 5.0, Applichem – Axonlab). The reaction was,
immediately after the appearance of color (ca. 1–2 min
after OPD addition), stopped with 10% sulfuric acid. Ab-
sorbance was measured at 450 nm by DTX 880 Multi-
mode Detector (Beckman-Coulter) and IgG concentration
(ng/mL) was determined by standard curve made by dilu-
tions of purified human IgG (Bethyl – LuBioScience).
In vitro assays:
IgG quantification in the supernatants of stimulated per-
ipheral white blood cells was done with the same ELISA
method as described above. Samples were diluted 10 fold
in PBS before loading to the plate.
Urine IgA concentration:
IgAtotal concentrations in thawed urine aliquots were
assessed by a standard indirect ELISA as follows: a 96-well
plate (Nunc MaxiSorp, Sigma-Aldrich) was coated with
capture antibody (Goat F(ab’)2 anti-human IgA-UNLAB,
Southern Biotech) 1:500 diluted in diluent (0.05%
Tween20 + 0.1% bovine serum albumin (BSA) (Albumin
fraction V, Applichem Panreac) in PBS). The plate was
subsequently incubated overnight at 4 °C, and then
washed with 0.05% Tween20 in PBS with a plate washer
(Beckman-Coulter). Non-specific binding sites were
blocked for 2 h at room temperature with blocking solu-
tion containing 1% BSA in PBS. After washing, thawed
urine aliquots - cleared of cell debris by centrifugation
and diluted 200 fold in diluent - were incubated for 2 h at
room temperature. Following another washing step, IgAto-
tal (Goat (F(ab’)2 anti-human IgA-biot, Southern Biotech)
detection antibodies were added 1:10′000 fold diluted in di-
luent for 2 h at room temperature. Followed another wash-
ing, a 1:8′000 diluted Streptavidin-HRP (Sigma-Aldrich)
solution was added to the wells and incubated for 45 min
at room temperature. IgA was determined by colorimetric
measurement of the product of the enzymatic reac-
tion mediated by HRP and o-phenylenediamine solu-
tion and the reaction was stopped with 10% sulfuric
acid. Absorbance was measured at 450 nm by DTX
880 Multimode Detector and IgA concentrations (ng/
mL) were determined from dilutions of purified hu-
man IgA (human IgA kappa-unlab, Southern Biotech).
Plasma cytokine measurements
The concentrations of cytokines and chemokines were
analyzed in the thawed plasma aliquot by Bio-Plex Pro
Cytokine, Chemokine and Growth Factor Assay (Bio-
Rad Laboratories AG) following the manufacturers
protocol: 40 μl of plasma were diluted fourfold in sample
dilution buffer. The standard curve concentration was
expanded 16-fold in the lower range which still resulted
in quantifiable amounts of standards and allowed the
measurements of lower cytokine levels. Data were col-
lected and analyzed using a Bio-Rad Bio-Plex 200 instru-
ment equipped with Bio-Plex Manager software (Bio-Rad).
We measured the concentrations of interleukin-2 (IL-2),
interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-
10 (IL-10), granulocyte-colony stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-
CSF), monocyte chemoattractant protein 1 (MCP1) and
tumor necrosis factor-alpha (TNF-α).
CMV serological status
Thawed plasma samples were tested for anti-
cytomegalovirus (CMV) IgG with a commercially available
ELISA kit (Cusabio Biotech Co.) according to producers
manual using 100 μl of plasma. A sample was considered
CMV positive when the measured absorption had a value
more than 2.1-fold increase compared to the provided
negative control.
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T-lymphocyte phenotyping
Peripheral blood lymphocytes (PBL) were thawed in a
water bath at 37 °C and immediately diluted 8-fold with
PBS containing 10% FBS. The suspension was centrifuged
at 210 g for 10 min and the supernatant was discarded.
After resuspension in 200 μl of PBS flow cytometric ana-
lysis of 200′000 cells/ tube was done for the following sur-
face markers: CD3-PerCP (clone SK7, BD biosciences),
CD4-APC (clone RPA-T4, BD bioscience), CD8-PE (clone
RPA-T8, BD biosciences) and the senescence associated
killer cell lectin-like receptor G1 (KLRG1-FITC, clone
SA231A2, BioLegend). Cells were incubated with 5 μl of
antibodies for 15 min at room temperature, centrifuged at
500 g for 5 min and the supernatant was removed. And
the cell pellet was resuspended in 200 μl PBS. Cell fluores-
cence was evaluated with FACScalibur flow cytometer
(BD Biosciences) and data were analyzed using FlowJo,
10.0 software (Tree star Inc., USA).
The discrimination of the different memory phenotypes
was also done with flow cytometry on freshly thawed cells
using the phenotypic subsetting of memory T cells based
on the work of Mahnke et al. [20] including the following
surface markers: CD4-APC (clone RPA-T4, BD bioscience),
CD8-APC (clone RPA-T8, BD bioscience), CD28-FITC
(clone CD38.2, BD bioscience), CD45Ro-PE (clone UCHL1,
BD bioscience) and CD95-PerCP-Cy5.5 (DX2, BD bio-
science). This analysis enables the discrimination between
naïve T cells (Tn: CD4 or CD8
+, CD45Ro−, CD28+, CD95−),
stem cell memory T cells (Tscm: CD4 or CD8
+, CD45Ro−,
CD28+, CD95+), central memory and transitional memory
T cells (Tcm + Ttm: CD4 or CD8
+, CD45Ro+, CD28+,
CD95+), effector memory (Tem: CD4 or CD8
+, CD45Ro+,
CD28−, CD95+) and terminally differentiated effector mem-
ory T cells (Tte: CD4 or CD8
+, CD45Ro−, CD28−, CD95+).
In vitro stimulation of IgG production and quantification
Frozen PBL were thawed in a water bath at 37 °C and then
directly diluted 8-fold with PBS + 10% FBS. The suspen-
sion was centrifuged at 210 g for 10 min, the supernatant
was discarded and the pellet resuspended in control
medium - RPMI-1640 medium (Amimed; Bio Concept)
supplemented with 10% FBS, penicillin–streptomycin
(100 units/ml) and amphotericin B (2.5 μg/ml - to reach a
concentration of 4 million cells/ml. This cell suspension
was kept overnight in a polypropylene Falcon tube allowing
gas exchange at humid 37 °C. The next morning a new cell
count was performed and 300′000 cells were plated per
well of a 96 U-bottom well plate (TTP, Switzerland) in
270 μl of either control (RPMI-1640 + 10% FBS) or stimu-
lating medium, all in duplicates. The used stimulation
medium is adapted from a previous work [21] and con-
sisted of 60 ng/ml human recombinant interleukin-2,
25 ng/ml Interleukin-10, 100 ng/ml Interleukin-21 (all from
BioBasic Inc.; Stephan Klee Trading and Consulting,
Switzerland), the synthetic unmethylated oligodeoxynucleo-
tide deoxycytosine-deoxyguanosine (CpG2429: tcgtcgttttcg
gcggccgccg, 360 nM [22]; Microsynth AG, Switzerland)
and 2.5 μg/ml pokeweed mitogen (Sigma-Aldrich,
Switzerland). The cell suspensions were incubated for
7 days at 37 °C in a humid atmosphere and 5% CO2
before measuring the IgG concentrations in the su-
pernatants as described above.
In vitro leucocyte proliferation assay
The thawed PBL, allowed to rest overnight as described
above, were used for an in vitro proliferation assay using
the fluorescent cell proliferation indicator CytoTell green
(AAT Bioquest; LuBioScience), according to the manufac-
tures protocol (20 min incubation at room temperature in
1:600 diluted dye). Cells (150′000 in 270 μl per well) were
plated in duplicates in a 96 U-bottom well plate (TTP,
Switzerland) either in control medium or in stimulation
medium with 2.5 μg/ml pokeweed mitogen or in stimula-
tion medium with 0.1% phytohaemagglutinin (PHA-M,
Sigma-Aldrich, Switzerland). The plates were incubated at
37 °C and 5% CO2 in humid atmosphere. Proliferative re-
sponses of the stimulated PBL and the controls were mea-
sured after 7 days of incubation by flow cytometry using
the intracellular dye dilution method and following sur-
face marker antibodies: CD3-PerCP (clone SK7, BD bio-
sciences), CD4-APC (clone RPA-T4, BD bioscience),
CD8-PE (clone RPA-T8, BD biosciences). Cells were incu-
bated with 5 μl of antibodies for 15 min at room
temperature, washed and resuspended in 200 μl PBS. Cell
fluorescence was assessed with FACScalibur flow cyt-
ometer and data were analyzed using the proliferation tool
of the FlowJo, 9.0 software.
Preparation of a medium containing killed bacteria for in
vitro PBL stimulation
Five of the most common urinary tract infection causing
bacterial strains from the clinical laboratory at Swiss
Paraplegic Centre, (Klebsiella pneumoniae, Proteus vul-
garis, Enterococcus sp., Staphylococcus aureus Rosenbach,
ATCC 29213, and Escherichia coli) were isolated from
urine sediment of SCI-patients. The bacteria were grown
overnight in thioglycolate broth at 37 °C. Inactivation
was achieved by addition of formaldehyde to a final con-
centration of 2.5% and an additional overnight incuba-
tion at room temperature. Inactivated bacteria were
washed three times with PBS to get rid of residual for-
maldehyde. A spectrophotometric (Diode array spectro-
photometer, WPA S2100, Biowave) semi-quantification
of the inactivated bacteria was done and the suspensions
were normalized to OD600 0.8. The five bacterial strains
were pooled together in an equal ratio and diluted 1′000
fold in RPMI-1640 medium supplemented with 10%
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FBS, penicillin–streptomycin (100 units/ml) and ampho-
tericin B (2.5 μg/ml) for final use.
Detection of bacteria-specific T-cells
Thawed PBL which were allowed to rest overnight, as
described above, were used for the in vitro bacterial
stimulation assay. 150′000 cells/well of a 96 U-bottom
well plate (TTP, Switzerland) were plated in duplicates
in 270 μl of either control medium or medium contain-
ing inactivated bacteria (as described above). The plate
was incubated at 37 °C and 5% CO2 in humid atmos-
phere. Flow cytometry was used to identify activated T-
lymphocytes at day four after plating. Analyzed were the
early activation induced surface antigens CD69 and
CD137. The measurement of CD69 and CD137 in-
creases the sensitivity and optical discrimination of rare
antigen specific T-cells [23, 24]. PBL were stained with
the following antibodies: CD4-FITC (clone RPA-T4, BD
bioscience), CD8-APC (clone RPA-T8, BD bioscience),
CD69-PerCP-Cy5–5 (clone FN50, BD bioscience) and
CD137-PE (clone 4B4–1, BioLegend). Cells were incu-
bated with antibodies for 15 min at room temperature,
washed and resuspended in PBS. Cell fluorescence was
evaluated with FACScalibur flow cytometer and data
were analyzed using FlowJo, 10.0 software. Activated
cells were characterized as being CD69+CD137+ and
the percentage of bacteria-specific T-cells was calculated
by subtracting percentage of the activated unstimulated
T-cells from the percentage of the activated bacterial
stimulated T-cells.
Telomere length analysis by PCR
Genomic DNA of freshly thawed PBL was extracted using
a commercial kit (Gentra Puregene Cell Kit Qiagen) fol-
lowing manufacturer’s instructions. Telomere length was
assessed using a quantitative PCR method as already de-
scribed elsewhere [25]. Briefly: Standard curves for the
telomeres and the reference gene 36B4 were done using
synthesized oligonucleotides. The DNA plasmid pBR322
(Sigma-Aldrich, Switzerland) was used to increase the
DNA content in the standards reaction mix to match the
DNA concentration of the isolated samples. Real-time
(RT)-PCR reactions were carried out in duplicates with,
4 ng/μL DNA template, and IQ SYBR Green Supermix
(Bio Rad). Specific products were amplified by a quantita-
tive PCR system (CFX96™ Real Time System, Bio Rad).
Real-time PCR was carried out with the following settings:
denaturation 95 °C, 5 min; followed by 30 amplification
cycles of 95 °C, 10 s; 60 °C, 30 s PCR reactions were car-
ried out in a final volume of 20 μL in 96-well PCR plates
(Bio Rad). Melting curve analysis was performed after the
amplification. Telomere and reference gene 36B4 starting
quantities were calculated using the standard curves.
Statistic tests
A sample size of 42 in each group was determined to be
sufficient to detect a one-fold difference in IgA antibody
concentration between the groups in the presence of a
100% variance with a power of 90% and a significance
level of 5%.
Data are presented as the mean and standard deviation
(SD) or the median and the interquartile range (IQR). The
data were tested for normal distribution using visual inter-
pretation of QQ-plots and the Kolmogorov-Smirnov test.
According to the distribution of the data, parametric or
non-parametric tests (Mann-Whitney U test) were used.
Statistics were computed using the SPSS Statistics, 24.0
software (IBM, Somers, USA).
Results
Demographics, UTI and CMV status of study participants
Table 1 summarizes the demographics and results of blood
and urine parameters of the four investigated groups.
A total of 169 volunteers participated in the study and
the mean age was similar between the SCI and control
groups (Table 1). Individuals of the oSCI group had sus-
tained SCI an average 16.2 years later in life than those of
the ySCI group, but the mean time of living with a SCI
was similar between the two groups. As expected, no case
of UTI, was found in the control groups. The laboratory
definition of UTI used in our investigation (> 1*105 bac-
terial colony forming units/ml urine and >90 leucocytes/
μl urine) allows the discrimination from bacteriuria with-
out the assessment of clinical UTI symptoms which are
difficult to measure in people with a SCI [26]. The UTI
prevalence of persons with SCI aged ≥60 years was about
50% higher compared to their younger counterparts. The
prevalence of past and current CMV infections, defined as
the presence of circulating anti-CMV IgG antibodies, was
greater in the older groups and was substantially higher in
the SCI population.
Blood biochemistry and peripheral blood leucocyte (PBL)
telomere length in the study participants
The measurements of a variety of parameters – including
immunoglobulins, cytokines and T-cell ratios (Table 2) -
revealed that serum total protein levels were significantly
lower in the ySCI group compared to the age matched
control group. No significant difference was observed in
the total plasma IgG levels between the four groups. We
measured the plasma levels of six immune related cyto-
kines interleukin (IL-) 2, IL-4, IL-10, granulocyte colony
stimulating factor (G-CSF), granulocyte macrophage col-
ony stimulating factor (GM-CSF) and monocyte chemo-
tactic protein 1 (MCP-1) and compared them between the
four groups (Table 2).
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Comparison between the age groups:
Generally, cytokine concentrations were more changing
with age in the able bodied group than in the SCI group.
The IL-2 plasma levels, a cytokine which is mostly pro-
duced by T-cells and promotes their growth, were
similar in all four groups. In the controls only, the anti-
inflammatory IL-4 and IL-10 were both significantly in-
creased with age. The chemoattractant protein MCP-1
showed a similar pattern: in the controls, it was signifi-
cantly increased with age, but there was no age effect in
the SCI population. Age independent levels of the gran-
ulocyte inducing GM-CSF were found in the controls,
but the SCI individuals showed a significant reduction
in GM-CSF plasma concentration with age. The neu-
trophil inducing G-CSF was significantly higher in
both older groups.
Comparison between SCI and controls:
People with SCI had a tendency to lower cytokine
concentrations compared with the able bodied controls.
IL-2 was significantly higher in the ySCI group com-
pared to the yCtr but there was no statistical difference
between oCtr and oSCI. G-CSF and MCP-1 had reduced
plasma concentrations in both age categories (younger
and older than 60 years). The difference of G-CSF levels
was significant between yCtr and ySCI, whereas the
difference of MCP-1 was significant between oCtr and
oSCI. IL-4 plasma concentrations were significantly
lower in ySCI and oSCI groups compared to their age
matched able bodied counterparts. No difference be-
tween controls and SCI groups was observed in the IL-
10 plasma concentrations. GM-CSF was significantly
elevated in the ySCI group compared with the yCtr
group. However, differences in GM-CSF concentrations
between oSCI and oCtr were insignificant.
PBL telomere length in study participants
Telomere length of peripheral blood mononuclear cells
(PBMC) and the CD4/CD8 ratio was measured and
compared between the groups (Table 2). Significant dif-
ferences in telomere length were found between the yCtr
and oCtr group. Differences between ySCI and oSCI, or
controls and SCI groups were insignificant.
Table 1 Demographics and prevalence of infections in study participants
yCtr (±SD) ySCI (±SD) oCtr (±SD) oSCI (±SD) yCtr-oCtr
(p-value)
ySCI-oSCI
(p-value)
yCtr-ySCI
(p-value)
oCtr-oSCI
(p-value)
N 42 42 42 43 N/A N/A N/A N/A
Age ± SD 42.8 ± 11 44.1 ± 9 67.6 ± 3 66.9 ± 6 <.001 0.68 <0.001 0.27
Time with SCI (y) N/A 15.7 ± 11 N/A 21.7 ± 19 N/A 0.26 N/A N/A
Age at SCI incident N/A 28.5 ± 11 N/A 44.7 ± 20 N/A <.001 ↑ N/A N/A
Para- / Tetraplegic ratio N/A 1.1 N/A 2.6 N/A N/A N/A N/A
UTI 0% 33% 0% 45% N/A N/A ↑ N/A N/A
CMV+ 52% 64% 69% 86% N/A ↑ N/A ↑ N/A N/A
Mean values are shown unless otherwise stated
SD standard deviation, N/A not applicable, SCI spinal cord injury, UTI urinary tract infections, CMV+ IgG anti cytomegalovirus present in plasma, ↑ ↓ increasing or
decreasing trend with age
Table 2 Blood biochemistry, CD4/8 cell ratio and PBL telomere length in study participants
yCtr (IQR) ySCI (IQR) oCtr (IQR) oSCI (IQR) yCtr-oCtr
(p-value)
ySCI-oSCI
(p-value)
yCtr-ySCI
(p-value)
oCtr-oSCI
(p-value)
Total prot. (mg/ml) 71.0 (4) 66.5 (7) 70.0 (5) 68.0 (7) 0.06 ↓ 0.16 ↔ <.001 0.30
pIgG (mg/ml) 10.7 (4) 9.8 (3) 10.2 (4) 9.7 (4) 0.28 ↔ 0.85 ↔ 0.30 0.82
IL-2 (pg/ml) 5.5 (3) 6.2 (5) 6.0 (2) 6.1 (2) 0.12 ↔ 0.27 ↔ <.01 0.70
IL-4 (pg/ml) 1.5 (0.6) 1.3 (0.2) 2.0 (1.1) 1.4 (0.5) <.01 ↑ 0.14 ↔ <.01 <.001
IL-10 (pg/ml) 3.6 (3) 2.9 (3) 5.0 (4) 3.9 (3) <.05 ↑ 0.12 ↔ 0.25 0.19
G-CSF (pg/ml) 26.3 (7) 25.0 (5) 31.0 (10) 26.9 (7) <.05 ↑ <.05 ↑ <.05 0.05
GM-CSF (pg/ml) 67 (25) 97 (50) 71 (30) 72 (35) 0.14 ↔ <.01 ↓ <.001 0.44
MCP-1 (pg/ml) 138 (28) 131 (20) 153 (43) 134 (27) <.05 ↑ 0.29 ↔ 0.10 <.01
CD4/8 (ratio) 2.4 (1.4) 2.1 (2.2) 3.0 (2.7) 2.9 (2.7) <.05 ↑ 0.08 ↑ 0.69 0.71
Telomere length PBL (Norm. to yCtr) 1 (0.5) 1.0 (0.4) 0.8 (0.3) 0.9 (0.3) <.05 ↓ 0.09↓ 0.44 0.07
Median values are shown
IQR inter quartile range is shown in brackets, N/A not applicable, SCI spinal cord injury, PBL peripheral blood leucocyte, ↑ ↓↔ increasing, decreasing or no trend
(p > 0.1) with age
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CD4/CD8 ratio in study participants
A CD4/CD8 ratio below 1 is an immune risk phenotype
criterion. Healthy ratio values are reported to be be-
tween 1 and 5. We observed that the ratio was increased
in the oCtr group compared with yCtr (Table 2). Statis-
tical differences was observed neither between oSCI and
ySCI nor between SCI and control groups. In total, only
6 study participants out of 169 had a CD4/CD8 ratio
below 1 (2× ySCI, 2× yCtr, 1× oSCI and 1× oCtr).
Inflamm-ageing in study participants
Figure 1 shows the plasma concentration of three pro in-
flammatory cytokines IL-6 (Fig. 1a), TNF-α (Fig. 1b) and
CRP (Fig. 1c) which were measured to assess the
inflamm-ageing status in the study participants. Controls
aged 60+ years had on average higher CRP and IL-6
concentrations compared to the young controls, whereas
in the SCI groups there was no difference between those
two cytokines. In average the oSCI group had significant
higher TNF-α levels compared with the ySCI. However
the difference in TNF- α concentrations was not signifi-
cant between the two control groups. The SCI popula-
tion had, independent of age, higher CRP, but lower
TNF-α levels compared with the able bodied control.
Urine IgA concentrations in study participants
The local secretion of IgA in the bladder was measured
by detection of IgA in the urine, shown on Fig. 2a. While
the mean values of urine IgA concentrations seemed
unaffected by age, they were strongly increased in SCI
persons, and some participants in the ySCI had very
high values (depicted as outliers) compared to the oSCI
group. The comparison of urine IgA concentrations in
SCI persons with and without an ongoing UTI is
depicted in Fig. 2b and shows that persons with an UTI
in both age categories have significantly higher IgA
levels. While the median difference in the concentration
of IgA levels between the young and old SCI groups with
an UTI was statistically insignificant, again there was a
large shift of mean IgA concentrations with a few very
high values observed in the ySCI whereas the oSCI had
more homogenous IgA urine levels.
White blood cell distribution among study participants
The abundancies of total leucocytes, neutrophils, lym-
phocytes, monocytes, eosinophils and basophils were
measured, and the results of the complete white blood
cell counts (WBC) are shown in Fig. 3. Total leucocytes
(Fig. 3a) concentration did not differ between oSCI and
ySCI but was reduced in the oCtr group compared to
yCtr. The observed difference in the total white blood
cells concentrations can be attributed to the lower con-
centrations of lymphocytes (Fig. 3c), and eosinophils
(Fig. 3e). In the SCI groups only the concentration of
the monocytes (Fig. 3d) is different between the two age
groups with higher levels in the oSCI cohort. The ySCI
group had lower lymphocyte concentrations compared
to the yCtr. No difference in cell concentrations of all
other leucocyte subtypes was observed between ySCI
and yCtr. In the 60+ years groups, the SCI group had
significantly higher neutrophil (Fig. 3b), lymphocyte and
monocyte counts compared to the controls.
Abundancy of memory T-cells
In the lymphocytes compartment, we measured T-cells in
five different stages of differentiation as shown in Table 3.
Flow cytometric analysis of T-cell surface markers such as
the co-stimulatory antigen CD28, the Fas receptor CD95,
the phosphatase receptor CD45ro and CD4 or CD8 was
used to gate on naïve- (Tn), stem cell memory- (Tscm),
central memory and transitional memory- (Tcm + Ttm),
effector memory- (Tem), and terminally differentiated ef-
fector memory T-cells (Tte).
Fig. 1 Inflamm-ageing markers among study participants. Inflamm-ageing status was assessed by measuring plasma IL-6 (a), plasma TNF-α (b)
and serum CRP (c) levels in the four study groups: able bodied controls <60 years (yCtr, n = 42), SCI < 60 years (ySCI, n = 41), able bodied
controls ≥60 years (oCtr, n = 42) and SCI ≥ 60 years (oSCI, n = 42). Results shown represent the median value for IL-6 and TNF-α and the mean
value for CRP. Error bars mark the 95% confidence intervals. Significant differences are indicated as *: p < 0.05, **: p < 0.01 and *** p < 0.001
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Comparison between the age groups
While there was no significant difference in the CD4 T-
cell subtypes between the age groups in able bodied con-
trols, the oSCI group had, compared to ySCI, higher
proportions of effector- and terminally- differentiated
memory T-cells. CD8 T-cells, seemed to be more af-
fected by age as seen in the decline of naïve cells. Similar
findings were observed in the SCI population with the
decline of naïve T-cells and the increase in effector- and
terminally differentiated memory T-cells.
Comparison between SCI and control
The comparison between the control and the SCI group
in the CD4 compartment revealed significant differences
in the cell memory phenotype abundancies. In both age
categories, the SCI group had less naïve- and higher cen-
tral memory T-cells than the control. In contrast to CD4,
the CD8 memory T-cell phenotype distributions were
more comparable between the control and SCI groups. As
a difference, ySCI individuals had less effector memory
CD8 T-cells than the age matched control. However, the
oSCI group had less naïve T-cells than the oCtr group.
In vitro stimulation assays, B-cells, T-cells and UTI burden
In vitro stimulation assays allow the assessment of the
immune cell function in a controlled setting. Figure 4
summarizes the results of the IgG production potential
and the T-cell specificity of in vitro stimulated PBL mix-
tures. IgG concentrations were measured at day 7 in the
supernatants of totally stimulated- (Fig. 4a) and with
UTI bacteria antigen stimulated PBL (Fig. 4b). The total
stimulation (cocktail of IL-2, IL-10, IL-21, pokeweed
mitogen and CpG rich DNA sequence) was considered
to be the maximum IgG production capacity. The max-
imum IgG production capacity was lower in the oSCI
group compared with ySCI. No significant difference
was observed between oCtr and yCtr. When PBL were
specifically stimulated with antigens from UTI bacteria,
(mix of Escherichia coli, Staphylococcus aureus, Klebsiella
pneumonia, Enterococcus sp. and Proteus vulgaris), the op-
posite was observed with significant lower IgG concentra-
tions in the oCtr group compared to the yCtr and no
difference in the SCI groups between ySCI and oSCI.
The abundancies of antigen specific CD4 (Fig. 4c) and
CD8 (Fig. 4d) T-cells were analysed in PBL stimulated
for four days with the UTI bacteria antigen mix. No stat-
istical difference was found between the groups in anti-
gen specific CD4 or CD8 T-cell abundancies.
In vitro T cell exhaustion and proliferation
The results of the phenotypic exhaustion, defined as
poor effector function, loss of high proliferative capacity
and the sustained expression of inhibitory receptors [27],
are shown in Fig. 5. The expression of the co-inhibitory
“killer cell lectin-like receptor G1” (KLRG-1) surface
marker has been postulated to be a marker of senes-
cence and exhaustion on T-cells [28] and was deter-
mined by flow cytometry for the CD4-positive (Fig. 5a)
and the CD8-positive (Fig. 5b) T-cells. The results indi-
cate a large inter-individual variance in the KLRG ex-
pression for both CD4 and CD8 T-cells. No statistical
difference in KLRG expression on CD4 T-cells was
found between the four groups. CD8 T-cells seemed to
be more affected by age, as both elder groups (oCtr and
oSCI) had significant higher proportions of KLRG+ cells
Fig. 2 Urine IgA concentrations in study participants. The upper panel
(a) shows the urine IgA log-values normalized to urine creatinine
concentrations for the four groups: able bodied controls <60 years
(yCtr, n = 42), SCI < 60 years (ySCI, n = 42), able bodied controls
≥60 years (oCtr, n = 42) and SCI ≥ 60 years (oSCI, n = 43). The bottom
panel (b) shows the urine IgA log-values normalized to urine creatinine
concentrations for the four groups: SCI < 60 years without active
urinary tract infection (UTI) (yCtr, UTI-, n = 28), SCI < 60 years with an
active UTI (ySCI, UTI+, n = 14), SCI ≥ 60 years without UTI (oSCI, UTI-,
n = 24) and SCI ≥ 60 years with UTI (oSCI, UTI+, n = 19). Significant
differences are indicated as *: p < 0.05 and *** p < 0.001
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compared to the young. No difference in KLRG+ cell ratios
was observed between the SCI and the control groups.
The proliferation potential as measured by the in vitro
cell division in response to the mitogen phytohaem-
agglutinin (PHA) was determined with flow cytometry at
day 7 by the rate of signal reduction of an intracellular
dye (Fig. 5c-f ). The number of responsive cells, defined
as the percent of cells which divided at least once, ob-
served between the four groups was neither different
for the CD4-positive (Fig. 5c) nor for the CD8-positive
(Fig. 5d) T-cells. However, cells from SCI study partici-
pants divided in average fewer times compared the ones
from the controls. The number of divisions for CD4 T-
cells (Fig. 5e) was significantly reduced between control
and SCI in both age categories whereas in the CD8 T-cell
compartment (Fig. 5f) the difference was only significant
between the oSCI and oCtr group. On the other hand, age
did not have an impact on the number of divisions.
Impact of SCI duration on immunosenescence parameters
An alternative analysis of data was performed in order
to see the impact of SCI duration on the immune frailty
parameters. The study participants were grouped ac-
cording to the duration of SCI in the more recent
(≤13.8 years with injury) and long-term (>13.8 years with
injury) SCI groups (Additional file 1: Table S1). The
Fig. 3 Leucocyte differential counts in study participants. Mean cell concentrations for leucocytes (a), neutrophils (b), lymphocytes (c), monocytes
(d), eosinophils (e) and basophils (f) are shown for the four groups: able bodied controls <60 years (yCtr, n = 42), SCI < 60 years (ySCI, n = 42),
able bodied controls ≥60 years (oCtr, n = 42) and SCI ≥ 60 years (oSCI, n = 43). Error bars mark the 95% confidence intervals. Significant
differences are indicated as *: p < 0.05, **: p < 0.01 and *** p < 0.001
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threshold of 13.8 years is the median value of SCI duration
among participants. Out of 39 compared parameters only
2 differed significantly. People who lived longer with a SCI
(>13.8 years) had higher GM-CSF plasma concentra-
tions and lower percentage of CD4 T-cells which
responded to an in vitro PHA stimulation assay as
described in section 2.9.
Discussion
The results of the study indicate that the immune sys-
tem in spinal cord injured (SCI) persons is altered to-
wards a more senescent phenotype, possibly due to a
higher antigen exposure of microbial origin - either bac-
terial or viral. The role of UTI in the onset of premature
immunosenescence remains unclear.
Table 3 Subtype abundancies of memory T-cells
yCtr (SD) ySCI (SD) oCtr (SD) oSCI (SD) yCtr-oCtr
(p-value)
ySCI-oSCI
(p-value)
yCtr-ySCI
(p-value)
oCtr-oSCI
(p-value)
N 41 42 42 41 N/A N/A N/A N/A
CD4 Tn % of CD4 47 (16) 39 (14) 49 (15) 39 (16) 0.66 ↔ 0.81 ↔ <0.05 <0.01
Tscm % of CD4 8.5 (3) 8.5 (3) 9.0 (4) 8.7 (3) 0.71 ↔ 0.73 ↔ 0.74 0.76
Tcm + tm % of CD4 42 (14) 50 (13) 39 (14) 48 (17) 0.27 ↔ 0.53 ↔ <0.01 <0.01
Tem % of CD4 2.0 (3) 1.4 (2) 1.9 (3) 2.3 (3) 0.94 ↔ <0.05 ↑ 0.57 0.23
Tte % of CD4 1.0 (1) 0.6 (1) 1.3 (4) 1.3 (2) 0.16 ↔ <0.01 ↑ <0.01 0.32
CD8 Tn % of CD8 32 (18) 34 (17) 19 (12) 14 (13) <0.001 ↓ <0.001 ↓ 0.48 <0.05
Tscm % of CD8 13 (7) 14 (8) 15 (10) 12 (6) 0.57 ↔ 0.52 ↔ 0.80 0.44
Tcm + tm % of CD8 28 (10) 32 (13) 32 (14) 39 (18) 0.21 ↔ 0.08 ↑ 0.21 0.12
Tem % of CD8 8.4 (6) 5.8 (4) 8.1 (6) 9.8 (10) 0.73 ↔ <0.05 ↑ <0.05 0.58
Tte % of CD8 19 (14) 14 (10) 26 (18) 25 (19) 0.11 ↔ <0.05 ↑ 0.19 0.83
Mean values are shown as percentage of total CD4 or CD8 T-cells
SD standard deviation is shown in brackets, N/A not applicable, Tn naïve-, Tscm central-, Tcm + tm central and transitional-, Tem effector-, Tte terminally
differentiated memory T-cell, ↑ ↓↔ increasing, decreasing or no trend (p > 0.1) with age
Fig. 4 In vitro functional assays of B-cells, T-cells and UTI burden. Median IgG concentrations were measured at day 7 in the supernatants of (a)
totally stimulated PBL (cultured with IL-2, IL-10, IL-21, pokeweed mitogen and CpG rich DNA sequence) and (b) stimulated, with antigens from
UTI bacteria (mix of inactivated E.coli, Staph. aureus, Klebsiella pneumonia, Enterococcus spec. And Proteus vulgaris). The bottom panels depict
the median abundancies of antigen specific CD4 (c) and CD8 (d) T-cells as measured as cells with upregulated surface activation markers (CD69
and CD137) after four days of stimulation with UTI bacteria antigens. Participants were split into four groups: able bodied controls <60 years (yCtr,
n = 41), SCI < 60 years (ySCI, n = 42), able bodied controls ≥60 years (oCtr, n = 42) and SCI ≥ 60 years (oSCI, n = 41). Error bars mark the 95%
confidence interval. Significant differences are indicated as **: p < 0.01
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Persons with a SCI had on average lower abundancies
of naïve- and higher concentrations of memory T-cells
when compared with the able bodied control group.
This increased shift from naïve to memory phenotype is
one of the few accepted hallmarks of immunosenescence
[29]. An interesting finding of our study was that the
abundancy of naive CD4 T-cells was already reduced
in the ySCI compared with yCtr. This suggests, as also
others found [4], that the decreased immune function oc-
curs early after an SCI and is maintained thereafter. Mem-
ory CD8 T-cell abundancies differed only between oSCI
and oCtr which suggests that CD8-T-cells from SCI indi-
viduals converted faster from naïve to memory phenotype
compared with the control.
T-cell exhaustion, the progressive loss of T-cell effector
functions - such as cytokine secretion and the ability for
high proliferative capacity - is also known to be caused by
some chronic infections [30, 31]. We measured lower re-
sponses to the stimulation with PHA in individuals with
SCI compared to able bodied controls. The CD4 T-cell re-
sponses were already reduced in the ySCI group, whereas
the CD8 T-cells differed only between oSCI and oCtr
Fig. 5 In vitro T-cell exhaustion and proliferation. The top row shows the expression of the surface exhaustion marker “killer cell lectin-like receptor G1”
(KLRG) as determined by flow cytometry for CD4 (a) and CD8 (b) T-cells (n = 41, 42, 42 and 41). The bottom four graphs show the results of a 7 days
in vitro stimulation of PBL with the mitogen PHA. Middle row depicts the percent of CD4 (c) and CD8 (d) T-cells which divided at least once or more
(n = 41, 39, 35 and 39). Bottom row represents the results for the average number of cell divisions for CD4 (e) and CD8 (f) T-cells after a 7 day in vitro
assay with PHA (n = 41, 39, 35 and 39). The horizontal mark indicates the median of each group: able bodied controls <60 years (yCtr), SCI < 60 years
(ySCI), able bodied controls ≥60 years (oCtr) and SCI ≥ 60 years (oSCI). Significant differences are indicated as *: p < 0.05 and *** p < 0.001
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groups. This finding strengthens our hypothesis that the
function of CD4 T-cells is affected early after SCI whereas
CD8 function changes faster with age. It should be noted,
that the number of cells starting division was the same
and only the number of divisions was different between
SCI and controls.
Unexpectedly, we observed an elevated initial con-
centration of circulating neutrophils and monocytes
in individuals with SCI, simultaneous to the advancing
senescence of the adaptive immune system and the in-
creased pathogen susceptibility. With age increasing
neutrophilia could be a sign of a higher antigen load or
chronic infections [32]. Further indications for an in-
creased antigenic load of the SCI population are mani-
fested in the elevated serum CRP, increased urine IgA, the
higher CMV prevalence and the high rate of active UTI.
Secretory IgA is known to be induced by the presence of
pathogens [33] and is an essential part of the mucosal
immunity with protective functions against bacteria in the
urinary tract. Generally, a SCI is a risk factor for increased
pathogenic antigen exposure at different locations. The
common necessity of urethral catheters (indwelling or
intermittent) to empty the bladder and the impaired in-
nervation of the bladder facilitate the occurrence of UTI
[34]. Artificial breathing devices, immobility, accumulation
of liquids in the lungs and the reduced ability of coughing,
further increase the risk for respiratory infections [35].
Additionally, due to immobility and the loss of sensation,
pressure sores or skin infections arise more likely [36].
Also the long hospital stay following the injury increases
the exposure to pathogens. In fact, based on our observa-
tions we speculate that the prolonged hospitalisation in-
creases the risk of an CMV infection, which in turn might
contribute to the observed immune alterations – a
hypothesis which we plan to test in a following project.
However, the question if recurrent UTI are causing a
premature onset of immunosenescence still remains un-
answered. On one hand, we were able to detect an age
conserved stable IgG response to bacterial antigens in
people with SCI (whereas the general population has a de-
creasing IgG response), but on the other hand, we did not
observe a higher proportion of specifically responding T-
cells in circulation. In contrast to chronic CMV infections
which can infect multiple cell- and tissue types [37], UTI
remain restricted to the urinary tract. Therefore it is pos-
sible that the occurrence of UTI bacteria specific memory
T-cells is compartmentalized to the urothelial tissue and
surrounding lymph nodes. These tissue resident memory
T-cells are found in several body compartments as de-
scribed elsewhere [38]. Longitudinal studies are necessary
to investigate the influence of SCI and recurrent UTI on
tissue resident memory T-cells and memory B-cells.
Fortunately, although some changes which point to-
wards an increased immunological strain and senescence
were found in persons with SCI, our study could not
fully support the hypothesis of a premature onset of
immune frailty of the type occurring in octo- and nona-
genarians [39]. Typically reported senescence traits as
increased inflamm-ageing, shortened PBL telomeres [40]
or increased proportions of exhaustions markers (KLRG-1)
[41] were similar or even lower in the SCI population com-
pared to the general population.
It is also possible, that the increased medication intake
in the SCI group, especially antidepressants and pain-
killers with anti-inflammatory properties, decreased the
plasma concentration of TNF-α [42]. In addition, the ob-
served increase of average PBL telomere length could be
a result of the elevated abundancy of innate immune
cells in SCI persons as previously seen in other patient
populations [43]. Importantly, the higher prevalence of
active UTI in the oSCI compared to the ySCI group
could be a sign of decreased immune defence in the age-
ing SCI patients.
Among the limitations of the study are its cross sec-
tional design and the wide range of SCI lesion levels. A
major discussion point is if our definition of the groups
is suitable to detect age-related changes in the immune
system. Given the reduced life expectancy of people with
SCI, the old SCI group with individuals ≥60 years was
relatively young in order to limit the selective survival bias
(Neyman-bias). Despite this precaution, we observed that
persons sustaining a SCI early in life were underrepre-
sented in the ≥60 years group. However, the duration of a
SCI seems not to affect the immune frailty parameters as
observed when analysing our data regarding the time
living with a SCI (Additional file 1: Table S1). Out of 39
compared parameters 37 did not differ between more
recently injured (≤13.8 years) and longer term injured
(>13.8 years) study participants.
Another limitation of the study is that we focused on
the adaptive immune system (especially T-cells), while the
obtained information on how SCI and aging impacted on
the innate immune system or the B-cells beyond antibody
production was limited. This gap is planned to be ad-
dressed in a following study.
Conclusions
The immune system of people with SCI shows traits of an
increased immunological strain and a premature onset of
immune frailty as manifested in higher UTI susceptibility in
people above 60 years. Further, persons with SCI had lower
proportions of naïve- and increased number of memory T-
cells, combined with reduced T-cell proliferation and higher
CMV prevalence compared to age matched controls.
The question if recurrent UTI are causing a premature
onset of immunosenescence still remains unanswered.
We observed an age conserved high IgG response to
bacterial antigens but the abundancy of UTI bacteria
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specific T-cells was comparable between the control and
SCI groups.
Data suggest that alterations in the CD4 T-cell compart-
ment, as described above, occur early after a SCI, already
in people <60 years, whereas CD8-T cells changes are ob-
served in ≥60 years old individuals.
Further studies - preferably longitudinal - are necessary
to investigate signs of immunosenescence in both the
adaptive immune system - such as tissue resident memory
T-cells, and memory B-cells - as well as in the cells of the
innate immune system among the aged SCI persons.
Additional file
Additional file 1: Table S1. Alternative analysis of data to see the impact
of SCI duration on the immune frailty parameters. The study participants were
grouped according to the duration of SCI in the more recent (≤13.8 years
with injury) and long-term (>13.8 years with injury) groups. Statistical signifi-
cance was done with a Mann-Whitney U test. (PDF 228 kb)
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